Humana Inc. (NYSE:HUM) Shares Sold by M&T Bank Corp

M&T Bank Corp trimmed its position in Humana Inc. (NYSE:HUM) by 33.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,573 shares of the insurance provider’s stock after selling 3,734 shares during the period. M&T Bank Corp’s holdings in Humana were worth $3,467,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rakuten Securities Inc. acquired a new stake in shares of Humana in the fourth quarter worth $25,000. Gradient Investments LLC lifted its holdings in shares of Humana by 200.0% in the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after buying an additional 40 shares during the period. Cetera Trust Company N.A purchased a new stake in shares of Humana in the fourth quarter worth about $28,000. Nvwm LLC grew its holdings in Humana by 41.0% during the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after acquiring an additional 25 shares during the period. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in Humana during the fourth quarter worth about $55,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

NYSE HUM opened at $324.63 on Wednesday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.67 and a current ratio of 1.67. The stock’s fifty day moving average is $323.08 and its two-hundred day moving average is $385.94. The firm has a market capitalization of $39.12 billion, a P/E ratio of 20.21, a price-to-earnings-growth ratio of 1.86 and a beta of 0.49. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $541.21.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the previous year, the firm earned $9.38 EPS. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. On average, research analysts anticipate that Humana Inc. will post 16.18 earnings per share for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.09%. Humana’s dividend payout ratio is currently 22.04%.

Insider Activity at Humana

In other Humana news, Director Jorge S. Mesquita bought 545 shares of Humana stock in a transaction on Tuesday, February 20th. The shares were bought at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the transaction, the director now directly owns 2,578 shares of the company’s stock, valued at $946,358.02. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 0.29% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

HUM has been the topic of several recent research reports. Oppenheimer lowered their price objective on Humana from $415.00 to $370.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Royal Bank of Canada dropped their price target on shares of Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Truist Financial reissued a “hold” rating and set a $550.00 target price on shares of Humana in a research note on Friday, January 19th. Mizuho dropped their target price on Humana from $550.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, January 26th. Finally, Bank of America reiterated a “neutral” rating and set a $342.00 price target (down previously from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Humana has a consensus rating of “Hold” and an average price target of $424.50.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.